###### Strengths and limitations of this study

-   This is the first international and multiperspective overview of costs and intangible effects associated with visual impairment and blindness.

-   The review is able to demonstrate a considerable impact of visual impairment and blindness.

-   The study synthesis of the reviewed literature was limited as no two studies used the same methodology, reported exactly the same outcomes or used the same sample population. Therefore a meta-analysis could not be conducted.

Introduction {#s1}
============

Visual impairment and blindness are foremost a problem of older age in all high-income countries and constantly increasing due to the ageing of populations.[@R1] Globally, the burden of disease related to vision disorders has increased by 47% from 12 858 000 disability adjusted life years (DALYs) in 1990 to 18 837 000 DALYs in 2010.[@R2] In high-income countries, health-related quality of life in severely visually impaired persons has been shown to be similar or even lower and emotional distress higher compared with other serious chronic health conditions such as stroke or metastasised solid tumours.[@R3] Blindness and visual impairment impact not only the individual but also the family, caregivers and the community, leading to a significant cost burden. In Australia, the overall cost placed visual disorders seventh among diseases, ahead of coronary heart disease, diabetes, depression and stroke in terms of economic burden on the health system.[@R4]

As demands on healthcare continue to increase in all high-income countries, economic evaluations of disease, impairment and interventions have also become increasingly important.[@R5] This necessitates a clear understanding of all aspects of the direct and indirect costs and intangible effects related to blindness and severe visual impairment, as almost all interventions in this area are aiming to prevent these and are often measured as an incremental cost effectiveness ratio (ICER), that is, the difference in cost compared to the difference in effectiveness. Similarly, faced with the increasing demand and limited resources in healthcare, these resources need to be prioritised, which again calls for a clear understanding of the economic impact of a disease or disorder. Against this background, we conducted a systematic review of the literature, collating all data available on the economic impact of VI&B.

Methods {#s2}
=======

The systematic review was conducted as suggested in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement which aims to improve the quality of systematic reviews by providing guidance and a 27-item checklist to aid in structuring methods and improving the reporting of results. It focuses on randomised trials, but can also be used as a basis for reporting systematic reviews of other types of research, for example, health economic evaluation studies. However, the checklist should not be used as a quality assessment instrument to measure the quality of included studies or the performed systematic review.[@R6] The completed PRISMA checklist for this review can be found in online supplementary appendix 3.

Literature search {#s2a}
-----------------

All economical and medical databases were searched from May to June 2012 through PubMed and OVID using the following terms""low vision", "visual impairment", "visually impaired", "blindness", "blind", "visual loss", "costs", "costs of illness"."

Subsequently, a second search was conducted using the main causes of visual impairment and blindness. Search terms were: '*low vision*'*,* '*visual impairment*'*,* '*visually impaired*'*,* '*blindness*'*,* '*blind*'*,* '*visual loss*'*,* '*costs*' combined with '*age-related macular degeneration*'*,* '*glaucoma*'*,* '*diabetic retinopathy*'*,* '*cataract*'*,* '*corneal opacities*'*,* '*childhood blindness*' separated by '*or*'.

Supplemental sources including references contained in identified articles were used in addition.

Two independent researchers screened identified articles using the following inclusion or exclusion criteria:

*Inclusion* Data for direct and indirect costs related to VI&B. Cost-of-illness---or in this case cost-of-impairment---studies can be divided into disease-specific and general studies. Both types of studies were included if they contained relevant data.Studies with outcomes related to intangible effects due to visual impairment and blindness.Overall data for burden of illness related to affected persons and carers.

*Exclusion* Costs pertaining to underlying diseases only with no specification of visual impairment levels.Economic studies conducted in developing countries.

As we were interested in the burden of VI&B in high-income countries only, we excluded economic studies conducted in developing countries. Health services provision and treatment options differ vastly between high-income and middle-income or low-income countries, making a comparison of cost categories unfeasible.

Cost classification {#s2b}
-------------------

All included articles were assessed as to which cost aspects they reported. Broadly, costs were divided into direct costs, indirect costs and intangible effects.[@R7]

Direct costs are defined as the actual expenses related to an illness and contain medical costs, non-medical costs and other direct costs.[@R5] Medical costs measure the cost of resources used for treating a particular illness. Non-medical costs are costs caused by the disease but not attributed to medical treatment. In case of VI&B, these are supporting services, assistive devices, home care, residential care or transportation (travel expenses). Other direct costs comprise informal care, time spent in treatment by patients or caregivers or time spent in rehabilitation, training, self-help groups or preventative activities.[@R5]

Indirect costs are defined as the value of lost output caused by reduced productivity due to illness or disability.[@R8]Patients and caregivers are affected by indirect costs due to allowances (financial support for income, residence, benefits), productivity losses (absenteeism, salary losses, part-time employment, loss of work) and dead-weight losses as well as years of life lost. Dead-weight loss, also known as an excess burden, is not a clearly defined concept. In a purely economic sense, dead-weight loss describes the costs to society created by market inefficiency. In the context of our study, we refer to it as an excess financial burden on society caused by VI&B.

Intangible costs or effects refer to the burden of illness of affected persons and caregivers, and comprise, among others, loss of well-being or loss of quality of life. It can be captured using questionnaires and expressed in DALYs. As this aspect of costs is difficult to quantify, DALYs or other measures of intangible effects are rarely assigned a monetary value.

Commonly, cost categories considered in a particular study depend on the perspective the study is conducted from, that is, a healthcare payer\'s (direct medical and non-medical costs only) or patient\'s perspective, or a societal perspective (all costs).

As cost categories varied considerably between all cost-of-illness studies, all different direct and indirect cost categories were listed in online supplementary appendix 2 prior to being categorised into our broader categories as outlined above.

Quality of included studies {#s2c}
---------------------------

A checklist, based on the assessment tool of Emmert *et al*[@R9] and extended by several questions covering relevant cost-of-illness aspects (see online supplementary appendix 1), was generated to assess the overall quality of included studies reporting direct or indirect costs of illness. The checklist contained sections on the study design, population, definition and specification of cost data and their limitations, including a total of 25 questions. Studies were rated from 0 to 100 for each of these categories. Two independent reviewers conducted the assessment and the interrater-reliability was assessed using κ (κ~n~) as suggested by Brennan and Prediger[@R10] for every study. The interpretation of the agreement was based on the agreement scale by Landis and Koch,[@R11] which indicates fair agreement at κ levels between 0.21 and 0.40, moderate agreement between 0.41 and 0.60, substantial agreement between 0.61 and 0.80 and almost perfect agreement between 0.81 and above.

Conversion of cost-of-illness study results {#s2d}
-------------------------------------------

For better comparison of costs across studies, the data were transformed: (1) costs were inflated to 2011 using a country-specific gross domestic product deflator, which takes fluctuating exchange rates, different purchasing power of currencies and the rate of inflation into account[@R12] [@R13] and (2) converted to USD using purchasing power parities (PPP).[@R14] PPPs account for differences in price levels between countries, and convert local currencies into international dollars by taking the purchasing power of different national currencies into account and eliminating differences in price levels between countries. The transformed values are presented in million units (million US\$ PPP) for total expenditures reported and in US\$ PPP for costs per person.

Results {#s3}
=======

The search yielded a total of 390 articles. After applying all inclusion and exclusion criteria, 22 studies were included in the systematic review ([figure 1](#BMJOPEN2013003471F1){ref-type="fig"}). Altogether, there were nine studies conducted in the USA, six studies conducted in Australia, two studies from France and Canada and one study from each of the following countries: Germany, the UK, Japan. All included studies are summarised in [table 1](#BMJOPEN2013003471TB1){ref-type="table"}.

###### 

Characteristics of included studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                            Country     Design and population                                                                                                                                                                                                                                                                                                                                                                                      Cost components evaluated                                                                Objective                                                                                                                                                                                                                                                                                                     Vision categories
  ----------------------------------------------------------------- ----------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  Bramley *et al*[@R15]                                             USA         Retrospective cohort analysis of a nationally representative Medicare 5% random sample; patients older than 65 years with newly diagnosed glaucoma; regression analysis                                                                                                                                                                                                                                    Direct medical costs, intangible effects                                                 To measure costs of visual impairment due to progressing glaucoma                                                                                                                                                                                                                                             No vision loss, moderate vision loss, severe vision loss, blindness

  Brezin *et al*[@R16]                                              France      National survey of a random stratified sample; 16 945 affected persons answered questionnaires; 4091 caregiver answered questionnaires                                                                                                                                                                                                                                                                     Indirect costs, intangible effects                                                       To document the prevalence of self-reported visual impairment and its association with disabilities, handicaps and socioeconomic consequences                                                                                                                                                                 Blind or light perception only, low vision, other visual problems and no visual problems

  Chou *et al*[@R17]                                                Australia   150 persons completed cost diaries for 12 months and were evaluated; costs categorised into four sections: (1) medicines, products and equipment, (2) health and community services, (3) informal care and support, (4) other expenses                                                                                                                                                                     Direct medical costs, direct non-medical costs                                           To describe and evaluate the process used to collect personal costs (out-of pocket) associated with vision impairment using diaries                                                                                                                                                                           ≥ 6/12 with restricted fields; \<612--6/18; \<6/18--6/60; \<6/60--3/60; \<3/60

  Clarke *et al*[@R18]                                              UK          Regression-based approach to estimate the short-term and long-term annual hospital and non-hospital costs associated with seven major diabetes-related complications in the UK Prospective Diabetes Study: myocardial infarction; stroke, angina or ischaemic heart disease; heart failure; blindness in one eye; amputation and cataract extraction; 5102 patients with newly diagnosed type 2 diabetes   Direct medical costs                                                                     To estimate the immediate and long-term health-care costs associated with seven diabetes-related complications                                                                                                                                                                                                Blind in one eye

  Cruess *et al*[@R19] (in combination with Gordon *et al*[@R20])   Canada      Prevalence-based approach; population projections for the whole population were compiled using data from the Statistics Canada 2006 Population Projections for Canada, Provinces and Territories 2001-2031                                                                                                                                                                                                 Direct medical costs, direct non-medical costs, indirect costs, intangible effects       To investigate costs of vision loss in Canada to inform healthcare planning                                                                                                                                                                                                                                   No details

  Frick *et al*[@R21]                                               USA         Retrospective cohort study; patients with blindness matched to non-blind selected from managed care claims database                                                                                                                                                                                                                                                                                        Direct medical costs                                                                     To evaluate total and condition-related charges incurred by blind patients in a managed care population in the USA                                                                                                                                                                                            Blind, non blind

  Frick *et al*[@R22]                                               USA         Data from the medical expenditure panel survey 1996---2002 for adults older than 40 years with visual impairment or blindness                                                                                                                                                                                                                                                                              Direct medical costs; direct non-medical costs; other direct costs; intangible effects   To estimate the economic impact of visual impairment and blindness in persons aged 40 years and older in the USA                                                                                                                                                                                              Visual impairment; blindness

  Javitt *et al*[@R23]                                              USA         Retrospective cohort analysis of a nationally representative Medicare 5% random sample, excluding Medicare managed-care enrollees                                                                                                                                                                                                                                                                          Direct medical costs                                                                     To assess and identify the costs to the Medicare programme for patients with either a stable or progressive vision loss and estimate the impact on eye-related and non-eye-related care                                                                                                                       Mild, moderate, severe vision loss (VA ≤20/200), blindness (VA ≤ 20/400)

  Keeffe *et al*[@R24]                                              Australia   114 participants of the Melbourne Visual Impairment Project completed diaries for 12 months; the burden of caregiver and opportunity costs for losses in work time was calculated (in combination with methods and data from Chou *et al*)                                                                                                                                                                 Other direct costs                                                                       To analyse prospective data on providers, types and costs of care for people with impaired vision in Australia                                                                                                                                                                                                VA \<20/40

  Kymes *et al*[@R25]                                               USA         Decision analytic approach; Markov model to replicate health events over the remaining lifetime of someone newly diagnosed with glaucoma                                                                                                                                                                                                                                                                   Incremental costs of illness                                                             To evaluate the incremental cost of primary open-angle glaucoma considering the visual and non-visual medical costs over a lifetime                                                                                                                                                                           No details

  Lafuma *et al*[@R26]                                              France      Interviews with a sample population (665 000) from a national survey of persons living in institutions or in the community (with a caregiver at home)                                                                                                                                                                                                                                                      Direct non-medical costs, other direct costs, indirect costs                             To estimate the annual national non-medical costs due to visual impairment and blindness                                                                                                                                                                                                                      Blind (light perception), low vision (better than light perception?, low vision and controls

  McCarty *et al*[@R27]                                             Australia   Population-based study; evaluation of the data from the Melbourne Visual impairment project; population ≥40 years was analysed in causes of death                                                                                                                                                                                                                                                          Intangible effects                                                                       To describe predictors of mortality in the 5-year follow-up of the Melbourne Visual impairment project                                                                                                                                                                                                        Visual acuity \<6/12

  Morse *et al*[@R28]                                               USA         2 552 350 discharges from hospital in the state of NY \>5.764 patients had visual impairment                                                                                                                                                                                                                                                                                                               Direct medical costs                                                                     To assess whether visual impairment contributes to the average length of stay within inpatient care facilities                                                                                                                                                                                                No details

  Porz *et al*[@R29]                                                Germany     Retrospective study of 66 patients using a cost-related and a vision-related quality of life questionnaire (impact of vision impairment questionnaire)                                                                                                                                                                                                                                                     Direct non-medical costs, intangible effects                                             To capture the costs of medicines, aids and equipment, support in everyday life and social benefits, as well as vision-related quality of life                                                                                                                                                                Visual acuity ≥0.3, Visual acuity \<0.3

  Rein, *et al*[@R30]                                               USA         Private insurance and Medicare claims data                                                                                                                                                                                                                                                                                                                                                                 Direct non-medical costs, indirect costs                                                 To estimate the societal economic burden and the governmental budgetary impact of the following visual disorders among US adults aged 40 years and older: visual impairment, blindness, refractive error, age-related macular degeneration, cataracts, diabetic retinopathy and primary open angle glaucoma   Refractive errors

  Roberts *et al*[@R31]                                             Japan       Prevalence-based approach; adopted using data on visual impairment, the national health system and indirect costs                                                                                                                                                                                                                                                                                          Direct medical costs, direct non-medical costs, indirect costs and intangible effects    To quantify the total economic cost of visual impairment in Japan                                                                                                                                                                                                                                             Low vision 6/12--6/60; blind \<6/60; visual impairment\>6/12

  Schmier *et al*[@R32]                                             USA         Using a questionnaire that included items on demographic and clinical characteristics and on the use of services, assistive devices and caregiving; 761 persons were included                                                                                                                                                                                                                              Direct non-medical costs, other direct costs                                             To assess the use of devices and caregiving among individuals with diabetic retinopathy and to evaluate the impact of visual acuity on use                                                                                                                                                                    Group 1 (20/20 or better), group 2 (20/ 25--20/30), group 3 (20/40--20/50), group 4 (20/60--20/70), or group 5 (20/80 or worse)

  Schmier *et al*[@R33]                                             USA         Survey with interviews on Daily Living Tasks Dependent on Vision Questionnaire; 803 respondents                                                                                                                                                                                                                                                                                                            Other direct costs                                                                       To assess the patient-reported use of caregiving among individuals with age-related macular degeneration and evaluation of impact of visual impairment level on this use                                                                                                                                      1\. VA \>20/32; 2. VA 20/32---\> 20/50;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  3. VA 20/50---\>20/80;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  4. VA 20/80---\> 20/150;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  5. 20/150---\>20/250;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  6. VA ≤ 20/250

  Vu, *et al*[@R34]                                                 Australia   Stratified random sample of 3040 participants from the Melbourne Visual Impairment Project; 2530 attended the follow-up study                                                                                                                                                                                                                                                                              Intangible effects                                                                       To investigate whether unilateral vision loss reduces any aspects of quality of life in comparison with normal vision                                                                                                                                                                                         Unilateral and bilateral vision loss (correctable and non-correctable)

  Wong *et al*[@R35]                                                Australia   Prospective cohort study; participants of any age to complete a diary for 12 months answering four categories: (1) medicines, products and equipment, (2) health and community services, (3) informal care and support and (4) other expenses                                                                                                                                                              Direct costs (medical and non-medical), other direct costs                               To determine the personal out-of-pocket costs of visual impairment and to examine the expenditure pattern related to eye diseases and the severity of visual impairment                                                                                                                                       Visual acuity ≥6/18 with constricted. fields;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \<6/18--6/60;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \<6/60

  Wood *et al*[@R36]                                                Australia   76 community-dwelling individuals with a range of severity of AMD; completing a diary for 12 months                                                                                                                                                                                                                                                                                                        Intangible effects; costs of adverse events                                              To explore the relationship between AMD, fall risk, and other injuries and identified visual risk factors for these adverse events                                                                                                                                                                            Binocular visual acuity, contrast sensitivity and merged visual fields
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AMD,age-related macular degeneration; IHD, ischaemic heart disease; MI, myocardial infarction; UKPDS, UK Prospective Diabetes Study; VA, visual acuity.

![Flow chart of the literature search.](bmjopen2013003471f01){#BMJOPEN2013003471F1}

All 17 of 22 studies dealing with direct or indirect costs of illness were rated above 50 for all four main quality aspects, indicating a sufficient level of quality, and consequently were included in the review (see [figure 2](#BMJOPEN2013003471F2){ref-type="fig"}). The interrater-reliability was consistently high and only a few discrepancies had to be settled by a discussion between the two raters. κ scores ranged from 0.34 to 0.76 ([figure 3](#BMJOPEN2013003471F3){ref-type="fig"}).

![Quality rating of included studies.](bmjopen2013003471f02){#BMJOPEN2013003471F2}

![κ-Index per study.](bmjopen2013003471f03){#BMJOPEN2013003471F3}

Of all the included studies, 12 captured direct medical costs, 10 direct non-medical costs and six other direct costs. Six studies reported data on indirect costs and 10 studies on intangible effects. All cost components reported by studies within each cost category are summarised in online supplementary appendix 2, highlighting the considerable variability in obtaining and reporting cost aspects related to VI&B between all studies.

Direct medical costs {#s3a}
--------------------

Direct medical costs occurred mostly due to hospitalisation, the use of medical services and medical products, and were reported either as incremental costs or, in some studies, provided as the length of hospital stay ([table 2](#BMJOPEN2013003471TB2){ref-type="table"}).

###### 

Results for direct medical costs

  Study                                                                                                   Cost outcomes                                                                                                                                         US\$ PPP in 2011
  ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Bramley *et al*[@R15]                                                                                   Annual costs per patient compared in degrees of vision impairment from no vision loss to onset of moderate or severe vision impairment or blindness   *** ***
  No vision loss **US\$8157**                                                                             **8695**                                                                                                                                              
  Moderate visual impairment **US\$13 162**                                                               **14 029**                                                                                                                                            
  Severe visual impairment **US\$15 312**                                                                 **16 321**                                                                                                                                            
  Blindness **US\$18 670**                                                                                **19 900**                                                                                                                                            
  Frick *et al*[@R22]                                                                                     Total expenditures on healthcare in blind and visually impaired persons ≥40 years                                                                     
  Blindness individual excess medical expenditures **US\$2157**                                           **2621**                                                                                                                                              
  Total excess medical expenditures **US\$2454 million**                                                  **2982 million**                                                                                                                                      
  Visual impairment individual excess medical expenditures **US\$1037**                                   **1260**                                                                                                                                              
  Total excess medical expenditure **US\$2661 million**                                                   **3233 million**                                                                                                                                      
  Total annual monetary impact for VI and blindness (primarily owing to home care) **US\$5100 million**   **6197 million**                                                                                                                                      
  Frick *et al*[@R21]                                                                                     Cohort with legally blind patients matched to an equal sample cohort with non-blind patients (annual costs per patient in the first year)             
  Blind persons mean costs **US\$20 677**                                                                 **24 180**                                                                                                                                            
  Median costs **US\$6854**                                                                               **8015**                                                                                                                                              
  Non-blind mean costs **US\$13 321**                                                                     **15 578**                                                                                                                                            
  Median costs **US\$371**                                                                                **434**                                                                                                                                               
  Javitt *et al*[@R23]                                                                                    Patients with normal vision compared to moderate or severe visual impairment or blindness regarding eye-related and non-eye-related care              
  Mean annual costs for eye-related care                                                                                                                                                                                                                        
  Normal vision **US\$370**                                                                               **445**                                                                                                                                               
  Moderate visual impairment **US\$345**                                                                  **415**                                                                                                                                               
  Severe visual impairment **US\$407**                                                                    **490**                                                                                                                                               
  Blindness **US\$237**                                                                                   **285**                                                                                                                                               
  Mean annual values for non-eye related costs                                                                                                                                                                                                                  
  Normal vision **US\$7928**                                                                              **9537**                                                                                                                                              
  Moderate visual impairment **US\$2193**                                                                 **2638**                                                                                                                                              
  Severe visual impairment **US\$3301**                                                                   **3971**                                                                                                                                              
  Blindness **US\$4443**                                                                                  **5345**                                                                                                                                              
  Kymes *et al*[@R25]                                                                                     Lifetime costs of POAG (primary open-angle glaucoma) to non-POAG patients                                                                             
  Incidence costs **US\$41 039**                                                                          **46 456**                                                                                                                                            
  Prevalence costs **US\$19 268**                                                                         **21 811**                                                                                                                                            
  Drug costs **US\$7098**                                                                                 **8035**                                                                                                                                              
  Incremental incidence costs **US\$27 326**                                                              **30 933**                                                                                                                                            
  Incremental prevalence costs **US\$5555**                                                               **6288**                                                                                                                                              
  Incremental drug costs **US\$4179**                                                                     **4731**                                                                                                                                              
  Morse *et al*[@R28]                                                                                     Extension of average length of stay in hospitals due to visual impairment                                                                             
  **5.2 days** longer stay                                                                                                                                                                                                                                      
  Cruess *et al*[@R19]                                                                                    Financial burden of vision loss to Canadian healthcare system                                                                                         
  Hospital **\$C1497.7 million**                                                                          **1934.72 million**                                                                                                                                   
  Physicians **\$C866.5 million**                                                                         **1119.34 million**                                                                                                                                   
  Vision care **\$C3483.7 million**                                                                       **4500.24 million**                                                                                                                                   
  Chou *et al*[@R17]                                                                                      The out-of-pocket expenses for medicines and products per person annually                                                                             
  **\$A206**                                                                                              **456**                                                                                                                                               
  Wong *et al*[@R35]                                                                                      Annual costs for medicine and products per patient                                                                                                    
  Visual acuity (VA) ≥6/18 with restr. field **\$A285**                                                   **632**                                                                                                                                               
  \<6/18---6/60=**\$A233**                                                                                **516**                                                                                                                                               
  \< 6/60=**\$A147**                                                                                      **326**                                                                                                                                               
  Clarke *et al*[@R18]                                                                                    Short-term and long-term annual hospital and non-hospital costs due to major diabetes-related complications                                           
  Blindness in one eye (in 20% of patients) **£ 4370**                                                    **4086**                                                                                                                                              
  Mean hospital in-patient costs **£872**                                                                 **815**                                                                                                                                               
  Roberts *et al*[@R31]                                                                                   Total economic costs of visual impairment                                                                                                             
  General medical expenditure **US\$8.102 billion**                                                       **8636 million**                                                                                                                                      
  In-patient **US\$1808 billion**                                                                         **1927 million**                                                                                                                                      
  Outpatient **US\$6.294 billion**                                                                        **6709 million**                                                                                                                                      
  Drugs **US\$1.395 billion**                                                                             **1487 million**                                                                                                                                      

POAG,primary open-angle glaucoma; VA,visual acuity.

At the onset of VI&B, the two major contributors to direct medical costs are hospitalisations and costs due to the increased use of medical services around diagnosis and treatment.[@R18] [@R19] [@R21] [@R22] [@R28] [@R31] Costs related to the recurrent hospitalisations and ongoing but less frequent use of medical services remain major cost components in persons with VI&B in the long term. Costs related to drugs, however, did not emerge as a major direct cost factor.[@R17] [@R35] All identified costs correlated with the degree of visual impairment leading to the highest expenditures being associated with blindness. The considerable differences in study methods and reported outcomes makes a head-to-head comparison of results by study or country or aggregation of data in terms of meta-analyses for direct medical costs very difficult. Several studies based on representative samples of Medicare beneficiaries in the USA reported mean annual expenses per patient to be US\$ PPP 12 175--14 029 for moderate visual impairment, US\$ PPP 13 154--16 321 for severe visual impairment and US\$ PPP 14 882--24 180 for blindness, which is almost a 100% excess of the estimated mean annual cost for non-blind patients at the upper end of the range ([table 2](#BMJOPEN2013003471TB2){ref-type="table"}).

Direct non-medical costs {#s3b}
------------------------

Assistive devices and aids, home modifications, costs for healthcare services such as home-based nursing or nursing home placements were the major contributors to direct non-medical costs ([table 3](#BMJOPEN2013003471TB3){ref-type="table"}). With worsening visual acuity, direct non-medical costs for support services and assistive devices increased from US\$ PPP 53.90 for a person with visual acuity ≥20/20 up to US\$ PPP 608.71 for a person with visual acuity ≤20/80.[@R32] Nursing home-placements and professional care costs incurred the highest expenditures followed by domestic modifications. These costs, however, were highest initially shortly after the loss of vision and in the majority were incurred only once ([table 3](#BMJOPEN2013003471TB3){ref-type="table"}).

###### 

Results for direct non-medical costs

  Study                                                                                                                   Cost outcomes                                                                                                                                                                       US\$ PPP in 2011
  ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Frick *et al*[@R22]                                                                                                     Total healthcare expenditures for adults ≥40 years (excess costs)                                                                                                                   *** ***
  Blindness home health agencies **US\$4988**                                                                             **6060**                                                                                                                                                                            
  Low vision home health agencies **US\$3105**                                                                            **3773**                                                                                                                                                                            
  Expenditures for private home health providers was **US\$1200 more** for the blind than the visually impaired persons                                                                                                                                                                                       
  Rein *et al*[@R30]                                                                                                      Total annual costs for visual impairment and blindness for adults ≥40 years                                                                                                         
  Nursing placements of **US\$10.96 billion**                                                                             **12 818 million**                                                                                                                                                                  
  Guide dogs **US\$0.062 billion**                                                                                        **72.5 million**                                                                                                                                                                    
  Independent living **US\$0.029 billion**                                                                                **33.9 million**                                                                                                                                                                    
  Schmier *et al*[@R32]                                                                                                   Annual costs for use of services and devices related to the degree of visual impairment per person                                                                                  
  Devices (glasses, sticks, computer software etc. **US\$109.79**                                                         **120**                                                                                                                                                                             
  Rehabilitation **US\$7.09**                                                                                             **7.78**                                                                                                                                                                            
  Chou *et al*[@R17]                                                                                                      Annual costs for health and community services per person                                                                                                                           *** ***
  Healthcare, home help, personal affairs, personal care, communication, transport, social activities **\$A 872**         **1932.50**                                                                                                                                                                         
  Expenditure for taxi, public transport, education expenses, guide dog **\$A 321**                                       **711**                                                                                                                                                                             
  Cruess *et al*[@R19]                                                                                                    Financial burden of vision loss to the Canadian healthcare system                                                                                                                   
  Care costs **\$C693 million**                                                                                           **895 21 million**                                                                                                                                                                  
  Aids and modification **\$C305 million**                                                                                **394 million**                                                                                                                                                                     
  Wong *et al*[@R35]                                                                                                      Annual personal costs for health and community services and other expenses per patient                                                                                              
  Median total costs **\$A1768**                                                                                          **3919**                                                                                                                                                                            
  Mean total costs **\$A3376**                                                                                            **7482**                                                                                                                                                                            
  Roberts *et al*[@R31]                                                                                                   Total economic costs of visual impairment                                                                                                                                           
  Meal service on admission **US\$0.149 billion**                                                                         **158.81 million**                                                                                                                                                                  
  Home-visit nursing **US\$0.013 billions**                                                                               **13.86 million**                                                                                                                                                                   
  Healthcare administration **US\$0.475 billion**                                                                         **506.30 million**                                                                                                                                                                  
  Community care **US\$6.608 billion**                                                                                    **7043 million**                                                                                                                                                                    
  Institutional care **US\$0.238 billion**                                                                                **253 68 million**                                                                                                                                                                  
  Vision aids **US\$0.2 billion**                                                                                         **213 18 million**                                                                                                                                                                  
  Porz *et al*[@R29]                                                                                                      Financial and psychological burden of retinal diseases divided into health economic relevant categories; annual expenses per person                                                 
  Aids for VA ≥0.3=**€96.65**                                                                                             **77.39**                                                                                                                                                                           
  VA \<0.3=**€83.58**                                                                                                     **66.92**                                                                                                                                                                           
  Personal assistance VA ≥0.3=**€454.96**                                                                                 **364 28**                                                                                                                                                                          
  VA \<0.3=**€667.77**                                                                                                    **534 68**                                                                                                                                                                          
  Lafuma *et al*[@R26]                                                                                                    National survey with estimation on costs of low vision and blindness for persons living in institutions or in the community (declared annually per person and total expenditures)   
  **Low vision; blindness**                                                                                               **Low-vision; blindness**                                                                                                                                                           
  Home modifications\* **€36.65 pp/year; €926.96 pp/year**                                                                **37.87; 957.90**                                                                                                                                                                   
  **€3.27 million total; €9.63 million total**                                                                            **3.375 million 9.95 million**                                                                                                                                                      
  devices\* **€184.14 pp/year; €387.35 pp/year**                                                                          **190.29; 400.28**                                                                                                                                                                  
  **€16.43 million total; €4.03 million total**                                                                           **16.98 million 4.165 million**                                                                                                                                                     
  home modification† **€42.23 pp/year; €121.12 pp/year**                                                                  **43.64; 125.16**                                                                                                                                                                   
  **€16.43 million total; €7.02 million total**                                                                           **16.98 million 7.25 million**                                                                                                                                                      
  devices† **€376.39; €363.14 pp/year**                                                                                   **388.95; 375.26**                                                                                                                                                                  
  **420 million total; €21.04 million total**                                                                             **434.02 million 21.74 million**                                                                                                                                                    
  paid assistance† **€1463.59 pp/year; €6750.66 pp/year**                                                                 **1512.446 976**                                                                                                                                                                    
   **€1635 million; €391 million total**                                                                                  **1690 million 404 million**                                                                                                                                                        

Other direct costs {#s3c}
------------------

Six of the included studies reported costs caused by informal care. Time spent on caring for or assisting visually impaired persons was related to the degree of visual impairment, with blind persons requiring the most assistance. The time spent by caregivers ranged from 5.8 h/week for a person with a visual acuity of \>20/32 and a cost of US\$ PPP 263 up to 94.1 h/week and costs of US\$ PPP 55 062 for persons with a visual acuity of ≤20/250.[@R33] All studies differed slightly as to the nature of direct costs assessed. Some studies reported on governmental, out-of-pocket expenses as well as opportunity costs, whereas others considered only one or two of these. The wide range of time and resources spent on informal care provision demonstrates the broad economic impact and considerable burden of informal care provision with concurrent expenses at a personal and societal level. Again, the reported cost aspects and methodologies differ considerably with, for example, Keeffe *et al*[@R24] reporting out-of-pocket expenses and Lafuma *et al*[@R26] reporting time spent on caring using an hourly rate. The multitude of differing approaches in each study does not allow for a head-to-head comparison but gives a comprehensive impression of the complex cost situation and highlights the importance of providing assistance to VI&B ([table 4](#BMJOPEN2013003471TB4){ref-type="table"}).

###### 

Results for other direct costs

  Study                                                                          Cost outcomes                                                                                                                                                                      US\$ PPP in 2011
  ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Frick *et al*[@R22]                                                            The economic impact of blindness and visual impairment on adults ≥40 years                                                                                                         
  Blindness causes mean individual excess informal care days 5.2                                                                                                                                                                                                    
  Visual impairment causes mean individual excess informal care days 1.2                                                                                                                                                                                            
  Blindness causes total excess informal care costs **US\$242 million**          **294.03 million**                                                                                                                                                                 
  Visual impairment total excess informal care costs **US\$124 million**         **150.66 million**                                                                                                                                                                 
  Schmier *et al*[@R32]                                                          Annual costs for caregiver time spent in supporting patients with macular degeneration                                                                                             
  **US\$5038**                                                                   **5526**                                                                                                                                                                           
  Schmier *et al*[@R33]                                                          Annual costs for quantity of caregiver time addicted to the degree of visual impairment per patient diabetic retinopathy                                                           
  Mean 5.7 h a day 5 days a week                                                                                                                                                                                                                                    
  oOverall amount of **US\$9572.77**                                             **11 194.40**                                                                                                                                                                      
  Keeffe *et al*[@R24]                                                           Personal out-of-pocket expenses regarding the burden of caregiver                                                                                                                  *** ***
  Median annual opportunity costs for work time spent on caregiving **\$A915**   **2244.60**                                                                                                                                                                        
  Wong *et al*[@R35]                                                             Annual median personal costs for informal care and assistance in activities of daily living                                                                                        
  For example, meal preparing, dressing, shopping, transportation **\$A2911**    **6451**                                                                                                                                                                           
  Lafuma *et al*[@R26]                                                           National survey with estimation on costs for time caregiver spent on low vision and blindness for persons in the community (declared annually per person and total expenditures)   
  **Low-vision; blindness**                                                      **low-vision; blindness**                                                                                                                                                          
  Informal care **€1881.81 pp/year; €7316.26 pp/year**                           **1944; 7560.48**                                                                                                                                                                  
  **€2101 million total; €424 million total**                                    **2171 million; 438 million**                                                                                                                                                      

Indirect costs {#s3d}
--------------

Studies of indirect costs demonstrate high expenditures related to productivity losses, changes in employment (employer and/or area of work), loss of income, premature mortality and dead-weight losses ([table 5](#BMJOPEN2013003471TB5){ref-type="table"}). Received social allowances were detailed in one study but not counted towards the overall costs as they were considered as transfer costs.[@R29] One study included the loss of caregivers' time, which is spent not only on support in terms of productivity loss but also as a loss of personal time and time to engage in leisure activities.[@R26] Equal to other cost components, indirect costs correlated with the degree of visual impairment, with the highest indirect costs reported for blind persons. Compared to all other cost categories, indirect costs due to productivity losses, lower employment rates and losses of income in patients as well as caregivers caused the highest economic burden. Annual estimates of productivity losses and absenteeism due to VI&B in the USA and Canada range from US\$ PPP 4974 to 5724 million, and are estimated to be US\$ PPP 7367 million for an overall decrease in workforce participation in the USA ([table 5](#BMJOPEN2013003471TB5){ref-type="table"}).

###### 

Results for indirect costs

  Study                                                                       Cost outcomes                                                                                                                                                                                                      US\$ PPP in 2011
  --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------
  Rein *et al*[@R30]                                                          Total annual indirect costs caused by visual disorders                                                                                                                                                             
  Decreased work force participation **US\$6.3 billion**                      **7367 million**                                                                                                                                                                                                   
  Decreased wages **US\$1.73 billion**                                        **2023 million**                                                                                                                                                                                                   
  Roberts *et al*[@R31]                                                       Indirect costs for visual impairment and blindness                                                                                                                                                                 
  Productivity losses **US\$4.667 billion**                                   **4974 million**                                                                                                                                                                                                   
  Lower employment **US\$4.230 billion**                                      **4509 million**                                                                                                                                                                                                   
  Absenteeism **US\$0.384 billion**                                           **409 million**                                                                                                                                                                                                    
  Premature mortality **US\$0.053 billion**                                   **56.5 million**                                                                                                                                                                                                   
  Dead-weight losses **US\$1.609 billion**                                    **1715 million**                                                                                                                                                                                                   
  Lafuma *et al*[@R26]                                                        National survey with estimation on indirect costs for losses of income in persons with low vision and blindness living in institutions or in the community (declared annually per person and total expenditures)   
  **low-vision; blindness**                                                   **low-vision; blindness**                                                                                                                                                                                          
  losses of incomes **€120.00 pp/year; €180.00 pp/year**                      **124; 186**                                                                                                                                                                                                       
   **€10.71 million total; €1.87 million total**                              **11.07 million 1.93 million**                                                                                                                                                                                     
  losses of incomes† **€3912.00 pp/year; €3168.00 pp/year**                   **4042; 3273**                                                                                                                                                                                                     
   **€4369 million total; €183.6 million total**                              **4515 million 189.72 million**                                                                                                                                                                                    
  Brezin *et al*[@R16]                                                        Prevalence and burden of blindness, low vision and visual impairment in the French community (estimation of monthly average value)                                                                                 
  **low-vision; blindness**                                                   **low-vision; blindness**                                                                                                                                                                                          
  Social allowances **€87; €364**                                             **92; 384**                                                                                                                                                                                                        
  Total household income **€1525; €1587**                                     **1607; 1673**                                                                                                                                                                                                     
  Household income no VI **€1851**                                            **1951**                                                                                                                                                                                                           
  Cruess *et al*[@R19]                                                        Indirect costs for Canada caused by vision loss                                                                                                                                                                    
  Employment participation, absenteeism, presenteeism **CAN\$4431 million**   **5724 million**                                                                                                                                                                                                   
  Dead-weight losses **\$C1757 million**                                      **2270 million**                                                                                                                                                                                                   

Intangible effects {#s3e}
------------------

Most studies used personal burden such as depression, emotional distress, loss of independency, loss of quality of life, limitations in activities of daily living or hazards such as falls and injuries to capture intangible effects of VI&B. Two studies, set in Japan and Canada, reported a loss of well-being as DALYs and an associated cost of US\$ PPP 51.8 billion and US\$ PPP 15.11 billion/year, respectively.[@R19] [@R31] Every reviewed study reported a high burden caused by multiple individual restrictions in patients and also in caregivers, which was found to be increasing with the degree of visual impairment ([table 6](#BMJOPEN2013003471TB6){ref-type="table"}). Mortality associated with visual impairment was reported to increase linearly from 4.5% in persons with normal visual acuity (≥20/20) to 22.2% in blind persons (visual acuity of \<20/200).[@R27] Measured as a restriction in caregivers, Brezin *et al*[@R16] reported an increase from 1.6% of caregivers of non-visually impaired persons, who reported restrictions in going out during the day, up to 12% for caregivers of blind patients.

###### 

Results for intangible effects

  Study                   Outcomes
  ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bramley *et al*[@R15]   Depression occurs in patients with vision loss more often (about 17%) than in patients with no vision loss, placements in nursing homes are demanded in 25.3% more, injuries happen in 33.4% more cases and femur fractures in 67.4% more cases
  Cruess *et al*[@R19]    Loss of well-being and loss in quality of life evokes 77 306 DALYs or rather \$C 11.7 billion in 2007 (US\$ PPP 15.11 billion in 2011)
  Vu *et al*[@R34]        Non-correctable unilateral vision loss was addicted to independent living and reduced safety; bilateral non-correctable vision loss was associated with nursing homes, emotional well-being, use of community services, and activities of daily living
  Wood *et al*[@R36]      Increased visual impairment was significantly associated with an increased incidence of falls and other injuries. 54% of participants had at least one fall, 30% had more than one fall and 63% of falls ended in injuries
  McCarty *et al*[@R27]   A linear increase of 5-year mortality correlating with a degree of visual impairment was detected; even mild visual impairment is related to a more than twofold risk of death
  Brezin *et al*[@R16]    A burden in patients occurs because of the inability to undertake daily activities; the need for assistance correlates with the degree of visual impairment; the burden on the caregiver was caused by the restricted possibilities for going out for different periods or losing social contacts, affected physical and mental welfare and modified professional activities
  Porz *et al*[@R29]      In a questionnaire with a score scale 0--100 points, patients with VA ≥0.3 achieved 79.32 for mobility and independency, 69.64 for emotional well-being and 73.86 for reading and achievement of information; persons with VA \<0.3 were rated with scores of 46.84, 61.43 and 44.25, respectively
  Roberts *et al*[@R31]   Loss of well-being was measured in DALYs; converted into a monetary value, this results in total annual costs of US\$ 48.598 billion (US\$ PPP 51.8 billion in 2011) and costs per capita of US\$ 29 690 per year (US\$ PPP 31 647)
  Frick *et al*[@R22]     The cases of blindness and visual impairment more than 209 000 QALY were projected to lost each year, this amounts to a monetary value of US\$ 10 000 million (US\$ PPP 12 150 in 2011)
                          

DALYs,disability adjusted life years; VA,visual acuity.

Discussion {#s4}
==========

In this first systematic review of costs associated with VI&B, we could demonstrate a considerable impact of VI&B in terms of the associated direct and indirect costs, as well as intangible effects such as loss of well-being, independence and excess mortality. The highest costs are caused by productivity losses in VI&B as well as their carers, followed by formal and informal caregiving, recurrent hospitalisations and the use of medical and supportive services in the VI&B. A much larger economic impact was due to intangible effects such as loss of independence, quality of life and excess morbidity. However, these are very difficult to quantify in monetary terms and only a small number of studies attempted this. All highlighted cost components as well as intangible effects which contribute to the overall economic impact of VI&B need to be considered in economic evaluations not only of VI&B but also of interventions aimed at averting these, depending on the focus of the economic evaluation.

A large proportion of the direct costs reported in reviewed studies are not directly related to eye-related medical care, but to falls and other accidents due to visual impairment, exacerbation of diabetes due to a reduced ability to self-manage, depression related to loss of vision and further excess morbidity.[@R23] Drug costs were not a major contributor to overall costs, which is mirrored in studies investigating chronic diseases such as diabetes mellitus, where---despite its ongoing use---hypoglycaemic drugs constitute only a small proportion of overall direct medical costs.[@R37] The annual mean costs of other potentially incapacitating chronic diseases such as diabetes mellitus (€5262 or US\$6889)[@R37] or the first year after a stroke (US\$14 361)[@R38] were much lower for diabetes and similar for the stroke estimate compared to the mean annual costs of severe VI&B.[@R15] [@R23] This is most likely due to the average diabetic not requiring professional caregiving of a scale required during the first year after a stroke or in severely VI&B. In severely VI&B, however, these costs are incurred every year following the loss of vision and do not decrease significantly over the following years unlike the reported annual costs for stroke.[@R38] Javitt *et al*[@R23] report all direct medical costs caused by visual impairment to amount to US\$2.14 million in 2003 in all non-institutionalised Medicare beneficiaries 69 years and older, and postulate a much higher cost for the whole of the US population. With the introduction of anti-Vascular-Endothelial-Growth-Factor treatment for a number of potentially blinding eye diseases such as neovascular age-related macular degeneration, diabetic macular oedema or macular oedema in retinal vein occlusions since all reviewed studies were conducted, the overall direct medical costs associated with visual impairment can be expected to be much higher today. This increase in cost is exacerbated by the ageing of populations in all developed countries as all major blinding diseases are age-related.[@R30]

Our finding that indirect costs are much higher than direct costs caused by VI&B is mirrored by virtually all other cost-of-illness studies assessing the economic impact of diseases or impairments which result in absenteeism and reduced ability to work.[@R39] [@R40] Back pain, for example, was found to cause considerable absenteeism and disablement, which---despite its significant hospital cost---lead to indirect costs constituting 93% of the overall costs in 1991 in the Netherlands.[@R40] Even in treatment and healthcare resource intensive chronic diseases such as diabetes mellitus, indirect costs pose more than half of the overall costs caused by the illness.[@R39]

All studies which assessed intangible effects in economic terms reported these to be the largest contributor to the overall economic impact of VI&B. Considering the adverse impact of losing vision on quality of life, independence and the ability to participate in society, this is not surprising. We and others have previously reported that even mild visual impairment (0.3\<LogMAR\<0.5) has a significant and independent impact on vision-specific functioning.[@R41; @R42; @R43] Similarly, emotional well-being is affected in patients with even mild vision impairment.[@R42] Depression is considered to result in further functional decline in this group by reducing motivation, initiative and resiliency.[@R44; @R45; @R46] Even unilateral vision loss had a measurable impact on falling and some other activities of independent living, with increased odds of having problems in many activities of daily life in a study conducted by Vu *et al*.[@R34] All this very adversely impacts the ability to participate in society, but also contributes to the considerable economic impact of intangible effects caused by VI&B.

There are several limitations which necessitate a careful interpretation of the overall findings. Using keywords to identify relevant literature always bears the potential of a too narrow focus, and not all the relevant literature may have been included. As we were interested in the economic burden of VI&B in high-income countries, we did not include (uncorrected) refractive error in our search terms as this is mostly a problem of middle-income and low-income countries, and excluded studies conducted in middle-income and low-income countries, which limits our results to high-income countries. Based on the searches conducted, as well as the cross-searching performed based on references, the authors are confident that the vast majority of the relevant literature could be included. To the authors' knowledge, a standardised quality checklist has not been used to assess economic evaluations of the impact of VI&B prior to inclusion in a systematic review until now. This further increases the overall quality of our review. The study synthesis of the reviewed literature was limited as no two studies used the same methodology, lacking a standardised definition and specification of cost components (see online supplementary appendix 2). Furthermore, no two studies reported exactly the same outcomes or used the same sample population. These problems have been reported for cost-of-illness---or in this case cost-of-impairment---studies in other areas, and adherence to existing cost-of-illness study guidelines is recommended.[@R12] [@R13] [@R47] Unfortunately, none of the reviewed studies seem to have adhered to any of the available international standards, and thus the overall comparability is limited. Similar to cost-of-illness studies in other areas, studies are summarised mostly descriptively or at a high level of aggregation.[@R12] The same applies to the chosen categories of visual impairment used in all studies, which differ considerably and further limit our ability to collate results ([table 1](#BMJOPEN2013003471TB1){ref-type="table"}).The perspective (affected person, healthcare payer, societal) of the study was only described in a minority of studies, and as highlighted in the results section, most studies were conducted in the USA and Australia, making inferences to other countries and healthcare systems difficult. However, this is the only systematic review of the economic impact of VI&B until now, highlighting the very broad economic impact and outlining the considerable scope that a comprehensive economic evaluation in this area should ideally have.

In conclusion, VI&B cause a considerable economic burden for affected persons, their caregivers and society at large, which increases with the degree of visual impairment for all assessed cost categories as well as intangible effects. This review highlights a large amount of cost categories which should be considered in economic evaluations in eye health, and future cost-of-illness or cost-of-impairment studies should adhere to the available guidelines to improve comparability. The review highlights the considerable amount of resources spent on caring for VI&B persons in the absence of a cure.
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